IL240983B - A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer - Google Patents

A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer

Info

Publication number
IL240983B
IL240983B IL240983A IL24098315A IL240983B IL 240983 B IL240983 B IL 240983B IL 240983 A IL240983 A IL 240983A IL 24098315 A IL24098315 A IL 24098315A IL 240983 B IL240983 B IL 240983B
Authority
IL
Israel
Prior art keywords
nanoparticles
albumin
composition
bladder cancer
limus drug
Prior art date
Application number
IL240983A
Other languages
English (en)
Hebrew (he)
Other versions
IL240983A0 (en
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of IL240983A0 publication Critical patent/IL240983A0/en
Publication of IL240983B publication Critical patent/IL240983B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
IL240983A 2013-03-14 2015-09-01 A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer IL240983B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786167P 2013-03-14 2013-03-14
US201361786175P 2013-03-14 2013-03-14
PCT/US2014/026564 WO2014151853A1 (en) 2013-03-14 2014-03-13 Methods of treating bladder cancer

Publications (2)

Publication Number Publication Date
IL240983A0 IL240983A0 (en) 2015-11-30
IL240983B true IL240983B (en) 2020-04-30

Family

ID=51581053

Family Applications (2)

Application Number Title Priority Date Filing Date
IL240983A IL240983B (en) 2013-03-14 2015-09-01 A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer
IL273856A IL273856A (en) 2013-03-14 2020-04-06 A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL273856A IL273856A (en) 2013-03-14 2020-04-06 A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer

Country Status (17)

Country Link
US (3) US9962373B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968191B1 (cg-RX-API-DMAC7.html)
JP (3) JP6309610B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150127187A (cg-RX-API-DMAC7.html)
CN (2) CN105246468A (cg-RX-API-DMAC7.html)
AU (2) AU2014236802B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022047A8 (cg-RX-API-DMAC7.html)
CA (1) CA2903548A1 (cg-RX-API-DMAC7.html)
ES (1) ES2881851T3 (cg-RX-API-DMAC7.html)
HK (1) HK1220405A1 (cg-RX-API-DMAC7.html)
IL (2) IL240983B (cg-RX-API-DMAC7.html)
MX (1) MX378934B (cg-RX-API-DMAC7.html)
NZ (1) NZ630213A (cg-RX-API-DMAC7.html)
RU (1) RU2015143490A (cg-RX-API-DMAC7.html)
SG (1) SG11201507234UA (cg-RX-API-DMAC7.html)
WO (1) WO2014151853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506877B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
MX380318B (es) * 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
RU2672875C1 (ru) * 2014-12-17 2018-11-20 Пфайзер Инк. Композиции PI3K/MTOR-ингибитора для внутривенного введения
HK1244847A1 (zh) * 2014-12-24 2018-08-17 豪夫迈．罗氏有限公司 用於膀胱癌症的治疗，诊断和预後方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016169042A1 (en) * 2015-04-24 2016-10-27 Genedia Biotech Co. Ltd. Combination therapies for bladder cancer
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
EA201890159A1 (ru) * 2015-06-29 2018-11-30 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2017016519A (es) * 2015-06-29 2018-08-16 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
NZ738929A (en) * 2015-06-29 2024-01-26 Abraxis Bioscience Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
WO2018064405A1 (en) * 2016-09-28 2018-04-05 Abraxis Bioscience, Llc Methods of treating mitochondrial and metabolic disorders
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
US20220054404A1 (en) * 2019-03-19 2022-02-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
WO2021096997A1 (en) * 2019-11-11 2021-05-20 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
WO2021258042A1 (en) * 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance
WO2022006596A1 (en) * 2020-06-30 2022-01-06 Northwestern University A single patient classifier for t1 high grade bladder cancer
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
BR9405798A (pt) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
NZ502500A (en) 1997-06-27 2002-03-28 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
AU784416B2 (en) 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
KR20110079741A (ko) 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
CA2662140A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008076257A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
MX380318B (es) 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
AU2013204187B2 (en) 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20100133475A (ko) 2008-04-10 2010-12-21 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 그의 용도
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
NZ593343A (en) 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
KR101739598B1 (ko) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 티오콜키신 유도체와의 조합 요법
AU2010233097B2 (en) 2009-04-10 2016-04-07 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
SG10201609290PA (en) * 2009-08-25 2016-12-29 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
EP2502078A1 (en) 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2575803B1 (en) 2010-06-02 2017-07-26 Abraxis BioScience, LLC Methods of treating bladder cancer
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
US20140155344A1 (en) 2010-06-07 2014-06-05 Neil P. Desai Combination therapy methods for treating proliferative diseases
CA2810842C (en) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
WO2014123612A1 (en) 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Methods of treating melanoma
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
HK1219231A1 (zh) 2013-03-13 2017-03-31 阿布拉科斯生物科学有限公司 治疗儿童实体瘤的方法
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US20170202782A1 (en) 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
MX2017016519A (es) 2015-06-29 2018-08-16 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
EA201890159A1 (ru) 2015-06-29 2018-11-30 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
NZ738929A (en) 2015-06-29 2024-01-26 Abraxis Bioscience Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer
US20180374583A1 (en) 2017-05-16 2018-12-27 Abraxis Bioscience, Llc Nomogram and survival predictions for pancreatic cancer

Also Published As

Publication number Publication date
AU2019201640A1 (en) 2019-04-04
WO2014151853A1 (en) 2014-09-25
US20200138793A1 (en) 2020-05-07
AU2014236802A1 (en) 2015-09-24
EP2968191A1 (en) 2016-01-20
JP2016513657A (ja) 2016-05-16
SG11201507234UA (en) 2015-10-29
US9962373B2 (en) 2018-05-08
RU2015143490A3 (cg-RX-API-DMAC7.html) 2018-03-13
US20180214425A1 (en) 2018-08-02
BR112015022047A2 (pt) 2017-07-18
AU2014236802B2 (en) 2019-01-03
NZ630213A (en) 2017-05-26
KR20150127187A (ko) 2015-11-16
BR112015022047A8 (pt) 2019-12-10
ZA201506877B (en) 2017-11-29
MX378934B (es) 2025-03-11
EP2968191A4 (en) 2016-11-16
HK1220405A1 (zh) 2017-05-05
IL273856A (en) 2020-05-31
JP2018062531A (ja) 2018-04-19
CN110934852A (zh) 2020-03-31
RU2015143490A (ru) 2017-04-26
MX2015011753A (es) 2015-12-07
IL240983A0 (en) 2015-11-30
ES2881851T3 (es) 2021-11-30
JP2020050680A (ja) 2020-04-02
CA2903548A1 (en) 2014-09-25
US20160008330A1 (en) 2016-01-14
CN105246468A (zh) 2016-01-13
US10413531B2 (en) 2019-09-17
EP2968191B1 (en) 2021-06-16
JP6309610B2 (ja) 2018-04-11

Similar Documents

Publication Publication Date Title
IL273856A (en) A preparation containing nanoparticles containing the drug Limousin and albumin for use in the treatment of bladder cancer
IL304851A (en) Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
PL3313401T3 (pl) Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych
IL242881B (en) A toxic substance for use in combination with radiation in cancer treatment
ZA201505735B (en) Cancer drug and uses
GB201319621D0 (en) Antimicrobial agents and their use in therapy
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3007694T3 (pl) Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego
GB2549865B (en) Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
PL3065759T3 (pl) Środki immunosupresyjne i ich zastosowanie w leczeniu
SG11201401971VA (en) Absorbent Body and Absorbent Article Comprising Absorbent Body
IL243171A0 (en) Polymeric nanoparticles of docetaxel for use in cancer treatment
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
ZA201602084B (en) Conformationally restrictred pi3k and mtor inhibitors
EP2961424A4 (en) ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
GB201308753D0 (en) Compounds and their use in therapy
GB201308217D0 (en) Compounds and their use in therapy
IL237227A0 (en) 520 -arry for use in the treatment of cancer in a patient with low aag
GB201312131D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy
ZA201508530B (en) Pyrazolopyridine derivatives for use in the treatment of bladder cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed